Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors